This Article  • References  • Full text PDF  • Send to a friend  • Save in My Folder  • Save to citation manager  • Permissions  Citing Articles  • Citation map  • Citing articles on HighWire  • Citing articles on Web of Science (100)  • Contact me when this article is cited  Related Content  • Similar articles in JAMA  Social Bookmarking   What's this?

Jonathan T. Edelson, MD; Anna N. A. Tosteson, ScD; Paul Sax, MD

JAMA. 1990;264(1):41-47.

Abstract
Patients who take nonsteroidal anti-inflammatory drugs (NSAIDs) are at increased risk of upper gastrointestinal tract bleeding, which may be prevented with prophylactic prescription of misoprostol. Using data from the literature, we estimated rates of gastrointestinal tract bleeding in NSAID users, direct medical costs, years of life lost, and cost-effectiveness of a 1-year course of misoprostol in three clinical populations of NSAID users: all users, users aged 60 years or older, and users with rheumatoid arthritis. The incremental cost-effectiveness ratios for misoprostol as primary prevention were $667 400 per year of life saved for all NSAID users; $186 700 per year of life saved for users aged 60 years or older; and $95 600 per year of life saved for users with rheumatoid arthritis. Misoprostol as secondary prevention for those who continued to take NSAIDs despite having had an episode of gastrointestinal tract bleeding in the previous year was associated with incremental cost-effectiveness ratios less than $40 000 per year of life saved in all patient groups. We conclude that misoprostol is costly as primary prevention for NSAID-induced gastrointestinal tract bleeding in the groups examined but may be cost-effective as secondary prevention in patients with a proved history of gastrointestinal tract bleeding.

(JAMA. 1990;264:41-47)

Author Affiliations
From the Division of General Medicine, Brigham and Women's Hospital (Drs Edelson and Sax), and the Division of Clinical Epidemiology, Departments of Medicine, Brigham and Women's, Beth Israel Hospital and Harvard Medical School (Drs Edelson and Tosteson), Boston, Mass. Dr Edelson is now with Medical Decision Resources Inc, Brookline, Mass.

Footnotes
Reprint requests to Medical Decision Resources Inc, 459 Washington St, Suite 3, Brookline, MA 02146 (Dr Edelson).

CiteULike    Connotea    Del.icio.us    Digg    Reddit    Technorati    Twitter     What's this?

THIS ARTICLE HAS BEEN CITED BY OTHER ARTICLES

Analysis of Aspirin-Associated Risks in Healthy Individuals
Hur et al.
The Annals of Pharmacotherapy 2005;39:51-57.
ABSTRACT | FULL TEXT  

Cost-Effectiveness of Aspirin Chemoprevention for Barrett's Esophagus
Hur et al.
JNCI J Natl Cancer Inst 2004;96:316-325.
ABSTRACT | FULL TEXT  

Cost Effectiveness of Aspirin, Clopidogrel, or Both for Secondary Prevention of Coronary Heart Disease
Gaspoz et al.
NEJM 2002;346:1800-1806.
ABSTRACT | FULL TEXT  

Cost-effectiveness of New Antiplatelet Regimens Used as Secondary Prevention of Stroke or Transient Ischemic Attack
Sarasin et al.
Arch Intern Med 2000;160:2773-2778.
ABSTRACT | FULL TEXT  

Systematic review of the cost effectiveness of prophylactic treatments in the prevention of gastropathy in patients with rheumatoid arthritis or osteoarthritis taking non-steroidal anti-inflammatory drugs
van Dieten et al.
Ann Rheum Dis 2000;59:753-759.
ABSTRACT | FULL TEXT  

Prevention of Nonsteroidal Anti-inflammatory Drug--Induced Gastrointestinal Mucosal Injury: A Meta-analysis of Randomized Controlled Clinical Trials
Koch et al.
Arch Intern Med 1996;156:2321-2332.
ABSTRACT  

NSAID Gastropathy: A New Understanding
Roth
Arch Intern Med 1996;156:1623-1628.
ABSTRACT  

Gastrointestinal Tract Complications of Nonsteroidal Anti-inflammatory Drug Treatment in Rheumatoid Arthritis: A Prospective Observational Cohort Study
Singh et al.
Arch Intern Med 1996;156:1530-1536.
ABSTRACT  

Practical Management of Osteoarthritis: Integration of Pharmacologic and Nonpharmacologic Measures
Griffin et al.
Arch Fam Med 1995;4:1049-1055.
ABSTRACT  

Has the Cost-effectiveness of Misoprostol Been Underestimated?-Reply
Stucki et al.
Arch Intern Med 1995;155:1451-1452.
ABSTRACT  

Has the Cost-effectiveness of Misoprostol Been Underestimated?
Gabriel
Arch Intern Med 1995;155:1448-1451.
ABSTRACT  

Is Misoprostol Cost-effective in the Prevention of Nonsteroidal Anti-inflammatory Drug--Induced Gastropathy in Patients With Chronic Arthritis? A Review of Conflicting Economic Evaluations
Stucki et al.
Arch Intern Med 1994;154:2020-2025.
ABSTRACT  

Setting Limits in Clinical Medicine
Murphy et al.
Arch Intern Med 1994;154:505-512.
ABSTRACT  

Evaluating Drugs after Their Approval for Clinical Use
Ray et al.
NEJM 1993;329:2029-2032.
FULL TEXT  

Cost-effectiveness Analysis of Various Strategies in the Diagnostic Management of Pulmonary Embolism
Oudkerk et al.
Arch Intern Med 1993;153:947-954.
ABSTRACT  

Cost-Conscious Prescribing of Nonsteroidal Anti-inflammatory Drugs for Adults With Arthritis: A Review and Suggestions
Greene and Winickoff
Arch Intern Med 1992;152:1995-2002.
ABSTRACT  

The Cost-effectiveness of Misoprostol
Hillman and Bloom
JAMA 1991;265:593-593.
ABSTRACT  

The Cost-effectiveness of Misoprostol
Roth
JAMA 1991;265:593-594.
ABSTRACT  

MISOPROSTOL COST-EFFECTIVE FOR SECONDARY PREVENTION OF BLEEDING FROM NSAIDS
JWatch General 1990;1990:6-6.
FULL TEXT  

How to Evaluate Drugs: Cost-effectiveness Analysis
Beck
JAMA 1990;264:83-84.
ABSTRACT